van Veen Kiril E B, Brouwer Matthijs C, van der Ende Arie, van de Beek Diederik
Department of Neurology, Center of Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, PO Box 22660, 1100DD, Amsterdam, the Netherlands.
Department of Neurology, Medical Center Haaglanden, The Hague, the Netherlands.
J Neuroimmune Pharmacol. 2017 Jun;12(2):213-218. doi: 10.1007/s11481-016-9705-6. Epub 2016 Sep 9.
We studied occurrence, presentation, disease course, effect of adjunctive dexamethasone, and prognosis of bacterial meningitis in patients using immunosuppressive medication. Patients were selected from our nationwide, prospective cohort on community-acquired bacterial meningitis performed from March 1, 2006 through October 31, 2014. Eighty-seven of 1447 episodes (6 %) of bacterial meningitis occurred in patients using immunosuppressive medication, and consisted of corticosteroids in 82 %. Patients with bacterial meningitis using immunosuppressive medication were less likely to present with headache (P = 0.02) or neck stiffness (P = 0.005), as compared those not on immunosuppressive medication. In 46 % of episodes CSF leukocyte count was below 1000/mm. CSF cultures revealed S. pneumoniae in 41 % and L. monocytogenes in 40 % of episodes. Outcome was unfavorable in 39 of 87 episodes (45 %) and death occurred in 22 of 87 episodes (25 %). Adjunctive dexamethasone was administered in 52 of 87 (60 %) episodes, and mortality tended to be lower in those on adjunctive dexamethasone therapy as compared to those without dexamethasone therapy (10 of 52 [19 %] vs 12 of 35 [34 %], P = 0.14). We conclude that bacterial meningitis in patients using immunosuppressive medication is likely to present with atypical clinical and laboratory features, and is often caused by atypical bacteria, mainly L. monocytogenes. Adjunctive dexamethasone is widely prescribed in these patients and was not associated with harm in this study.
我们研究了使用免疫抑制药物的患者中细菌性脑膜炎的发生率、临床表现、病程、辅助使用地塞米松的效果及预后。患者选自我们于2006年3月1日至2014年10月31日进行的全国性社区获得性细菌性脑膜炎前瞻性队列研究。1447例细菌性脑膜炎发作中有87例(6%)发生在使用免疫抑制药物的患者中,其中82%使用了皮质类固醇。与未使用免疫抑制药物的患者相比,使用免疫抑制药物的细菌性脑膜炎患者出现头痛(P = 0.02)或颈部僵硬(P = 0.005)的可能性较小。在46%的发作中,脑脊液白细胞计数低于1000/mm³。脑脊液培养显示,41%的发作中分离出肺炎链球菌,40%的发作中分离出单核细胞增生李斯特菌。87例发作中有39例(45%)预后不良,87例发作中有22例(25%)死亡。87例发作中有52例(60%)使用了辅助地塞米松,与未使用地塞米松治疗的患者相比,接受辅助地塞米松治疗的患者死亡率有降低趋势(52例中有10例[19%] vs 35例中有12例[34%],P = 0.14)。我们得出结论,使用免疫抑制药物的患者发生的细菌性脑膜炎可能具有非典型的临床和实验室特征,且常由非典型细菌引起,主要是单核细胞增生李斯特菌。辅助地塞米松在这些患者中广泛应用,且在本研究中未发现有害作用。